Gland Pharma reported strong Q1FY27 results with 20% revenue growth and 47% PAT growth. Management highlighted a major strategic CDMO contract and raised long-term CAGR outlook to 20% following recent business wins.
Gland Pharma reports a strong start to FY27, driven by CDMO and B2B growth, though currency shifts significantly impacted the bottom line compared to the previous quarter.
Gland Pharma reported Q1FY27 revenue of ₹18,003 Mn (20% YoY) with PAT of ₹3,170 Mn (47% YoY). Growth was driven by CDMO product launches and B2B volume expansion in US and Europe.
